查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1781969

受限胜肽药物市场，按胜肽类型、按治疗领域、按合成方法、按给药途径、按最终用户、按国家和地区划分 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Constrained Peptide Drugs Market, By Peptide Type, By Therapeutic Area, By Synthesis Method, By Route of Administration, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年受限肽类药物市场规模价值 15.6032 亿美元，2025 年至 2032 年的复合年增长率为 16.20%。

受限的胜肽类药物市场-市场动态

慢性病盛行率上升推动市场需求

慢性病盛行率的上升推动了全球限制性胜肽类药物市场的成长。根据美国疾病管制与预防中心的数据，美国约有十分之六的成年人患有慢性病，这推动了对限制性胜肽类药物等标靶疗法的需求。此外，在肽类药物稳定性方面的进步预计将是推动市场成长的另一个因素。然而，高昂的生产成本和监管挑战预计将在未来几年阻碍市场的成长。相反，肿瘤学应用的不断扩展以及个人化治疗投资的增加，为针对个别患者情况设计的胜肽类药物提供了机会。

受限胜肽类药物市场—关键洞察

根据我们的研究分析师的分析，预测期内（2025-2032 年）全球市场预计年复合成长率约为 16.20%

根据胜肽类型细分，预计环化胜肽将在 2024 年占据最大市场份额

根据治疗领域细分，肿瘤学是 2024 年领先的治疗领域

根据合成方法细分，固相胜肽合成是 2024 年最主要的合成方法

根据给药途径细分，皮下注射是 2024 年最主要的给药途径

根据最终用户细分，医院是 2024 年领先的最终用户

按地区划分，北美是 2024 年最大的收入来源

受限胜肽药物市场-細項分析：

全球受限胜肽药物市场根据胜肽类型、治疗领域、合成方法、给药途径、最终用户和地区进行细分。

根据胜肽的类型，市场分为四大类：环肽、大环肽、D肽和钉合肽。预计环肽将在预测期内占据主要市场份额，这得益于其与其他类型的肽相比，稳定性更高、生物利用度更高，并且在治疗领域应用更广泛。

根据治疗领域，市场分为两类：传染病、心血管疾病、中枢神经系统疾病、肿瘤和代谢失调。由于癌症盛行率的上升以及肽类药物在标靶癌症治疗中的有效性，预计肿瘤领域将在全球受限肽类药物市场中占据主要份额。

受限胜肽类药物市场—地理洞察

预计在预测期内，北美地区将占据主要的胜肽类药物市场份额，这得益于其先进的医疗基础设施、不断增加的研发投入以及创新疗法的广泛采用。同时，由于医疗保健意识的提高、患者人数的增加以及新兴经济体对生物技术和製药行业的投资不断增加，预计亚太地区将以最快的速度成长。

受限胜肽类药物市场-竞争格局：

对标靶和稳定疗法的需求不断增长，推动了受限肽类药物的创新。各公司专注于推进肽类药物的稳定技术和优化给药方法，以提高疗效和患者依从性。与研究机构建立策略伙伴关係和合作，加速了药物开发并拓展了产品线。此外，在扩大生产能力和开拓新兴市场方面的投资有助于满足日益增长的医疗保健需求。对个人化医疗和新型胜肽类药物剂型的重视，进一步增强了公司在不断变化的市场格局中的竞争优势。

最新动态：

2025 年 1 月，Bicycle Therapeutics plc 分享了泽来奈肽培维多汀与派姆单抗治疗不适用顺铂的转移性尿路上皮癌患者的 1 期联合用药最新结果，以及 2025 年的主要成就和战略计划。

目录

第 1 章：受限胜肽药物市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 受限制的胜肽类药物市场片段（按肽类划分）
    • 受限制的胜肽类药物市场片段（按治疗领域）
    • 受限胜肽类药物市场片段（依合成法）
    • 受限制的胜肽类药物市场片段（依给药途径）
    • 受最终用户限制的胜肽类药物市场片段
    • 受限制的胜肽类药物市场（按国家/地区）
    • 受限制的胜肽类药物市场片段（按地区）
  • 竞争洞察

第三章：受限胜肽药物关键市场趋势

  • 肽类药物市场驱动因素受限
    • 市场驱动因素的影响分析
  • 肽类药物市场限制因素
    • 市场限制的影响分析
  • 受限的胜肽类药物市场机会
  • 肽类药物市场未来趋势受限

第四章：受限胜肽类药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：受限制的胜肽类药物市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：受限的胜肽类药物市场格局

  • 2024年受限肽类药物市场份额分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：受限胜肽药物市场－依胜肽类型

  • 概述
    • 按肽类型分類的细分市场份额分析
    • 环化胜肽
    • 大环肽
    • D-胜肽
    • 订书钉胜肽

第八章：受限胜肽药物市场-依治疗领域

  • 概述
    • 按治疗领域分類的细分市场占有率分析
    • 传染病
    • 心血管疾病
    • 中枢神经系统疾病
    • 肿瘤学
    • 代谢紊乱

第九章：受限胜肽药物市场－依合成方法

  • 概述
    • 细分市场占有率分析（采用综合法）
    • 固相胜肽合成
    • 重组技术

第 10 章：受限胜肽药物市场 - 按给药途径

  • 概述
    • 按治疗领域分類的细分市场占有率分析
    • 口服
    • 静脉
    • 透皮
    • 皮下

第 11 章：受限胜肽药物市场 - 按最终用户

  • 概述
    • 按最终用户细分的份额分析
    • 医院
    • 研究机构
    • 製药公司

第 12 章：受限胜肽药物市场-按地域划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美受限制的胜肽类药物主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按肽类型）
    • 北美市场规模及预测（按治疗领域）
    • 北美市场规模及预测（综合法）
    • 北美市场规模及预测（按给药途径）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲受限制的胜肽类药物主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（按胜肽类型）
    • 欧洲市场规模及预测（按治疗领域）
    • 欧洲市场规模及预测（综合法）
    • 欧洲市场规模及预测（依管理途径）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区受限胜肽类药物主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依胜肽类型）
    • 亚太地区市场规模及预测（依治疗领域）
    • 亚太地区市场规模及预测（依综合法）
    • 亚太地区市场规模及预测（依管理途径）
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲受限肽类药物主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按肽类型）
    • 拉丁美洲市场规模及预测（按治疗领域）
    • 拉丁美洲市场规模及预测（依综合法）
    • 拉丁美洲市场规模及预测（依管理途径）
    • LATAM 规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲受限肽类药物主要製造商
    • 中东和非洲市场规模及预测（按国家/地区）
    • 中东和非洲市场规模及预测（按胜肽类型）
    • 中东和非洲市场规模及预测（按治疗领域）
    • 中东及非洲市场规模及预测（综合法）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 13 章：关键供应商分析-受限胜肽药物产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Amgen Inc.
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Sanofi SA
    • Bicycle Therapeutics PLC
    • Bristol-Myers Squibb Company
    • Aileron Therapeutics, Inc.
    • Eli Lilly and Company
    • Aileron Therapeutics Inc.
    • Spexis AG
    • Santhera Pharmaceuticals
    • Protagonist Therapeutics Inc.
    • Union Chimique Belge SA (UCB)
    • Biosynth (Pepscan)
    • Creative Peptides
    • Pepticom Ltd.
    • Bio-Synthesis Inc.
    • PeptiDream Inc.
    • CPC Scientific Inc.
    • Chugai Pharmaceutical Co. Ltd.
    • Circle Pharma
    • Others

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5366

REPORT HIGHLIGHT

Constrained peptide drugs market size was valued at US$ 1,560.32 Million in 2024, expanding at a CAGR of 16.20% from 2025 to 2032.

Constrained peptide drugs are specially designed molecules where the peptide's structure is chemically "locked" into a stable shape. This constraint improves their stability, enhances binding to specific targets, and increases resistance to degradation by enzymes in the body. These features make them highly effective in treating diseases by precisely interacting with biological molecules, offering advantages over traditional peptides such as improved potency, selectivity, and longer-lasting therapeutic effects.

Constrained Peptide Drugs Market- Market Dynamics

Increasing prevalence of chronic diseases to propel market demand

The rising prevalence of chronic diseases is driving the growth of the global constrained peptide drugs market. According to the CDC, approximately 6 in 10 adults in the U.S. have a chronic disease, driving demand for targeted therapies like constrained peptide drugs. Besides, advancements in peptide stabilization is another factor projected to boost the market growth. However, high production costs and regulatory challenges is expected to hamper the market growth in the coming years. On the contrary, expanding applications in oncology and increasing investment in personalized, providing opportunities for peptide drugs designed for individual patient profiles.

Constrained Peptide Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.20% over the forecast period (2025-2032)

Based on Peptide Type segmentation, cyclized peptides was predicted to show maximum market share in the year 2024

Based on Therapeutic Area segmentation, oncology was the leading Therapeutic Area in 2024

Based on Synthesis Method segmentation, solid phase peptide synthesis was the leading Synthesis Method in 2024

Based on Route of Administration segmentation, subcutaneous was the leading Route of Administration in 2024

Based on end user segmentation, Hospital was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Constrained Peptide Drugs Market- Segmentation Analysis:

The Global Constrained Peptide Drugs Market is segmented on the basis of Peptide Type, Therapeutic Area, Synthesis Method, Route of Administration, End User, and Region.

The market is divided into four categories based on Peptide Type: cyclized peptides, macrocyclic peptides, D-peptides, and stapled peptides. The cyclized peptides segment is expected to hold the major market share during the forecast period, driven by their enhanced stability, improved bioavailability, and widespread applications in therapeutic areas compared to other peptide types.

The market is divided into two categories based on Therapeutic Area: infectious diseases, cardiovascular diseases, Cns Disorders, oncology, and metabollic disorders. The oncology segment is expected to hold the major market share in the global constrained peptide drugs market, due to increasing cancer prevalence and the effectiveness of peptide drugs in targeted cancer therapies.

Constrained Peptide Drugs Market- Geographical Insights

The North America region is expected to hold the major constrained peptide drugs market share during the forecast period, driven by advanced healthcare infrastructure, increased R&D investments, and high adoption of innovative therapies. Meanwhile, the Asia-Pacific region is projected to grow at the fastest rate due to rising healthcare awareness, expanding patient populations, and growing investments in biotechnology and pharmaceutical sectors across emerging economies.

Constrained Peptide Drugs Market- Competitive Landscape:

Rising demand for targeted and stable therapeutics drives innovation in constrained peptide drugs. Companies focus on advancing peptide stabilization technologies and enhancing delivery methods to improve efficacy and patient compliance. Strategic partnerships and collaborations with research institutes accelerate drug development and expand product pipelines. Additionally, investments in expanding manufacturing capabilities and penetrating emerging markets help capitalize on growing healthcare needs. Emphasis on personalized medicine and novel peptide formats further strengthens competitive positioning in this evolving landscape.

Recent Developments:

In January 2025, Bicycle Therapeutics plc shared updated Phase 1 combination results for zelenectide pevedotin with pembrolizumab in cisplatin-ineligible metastatic urothelial cancer patients, along with key accomplishments and strategic plans for 2025.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sanofi S.A.
  • Bicycle Therapeutics PLC
  • Bristol-Myers Squibb Company
  • Aileron Therapeutics, Inc.
  • Eli Lilly and Company
  • Aileron Therapeutics Inc.
  • Spexis AG
  • Santhera Pharmaceuticals
  • Protagonist Therapeutics Inc.
  • Union Chimique Belge S.A. (UCB)
  • Biosynth (Pepscan)
  • Creative Peptides
  • Pepticom Ltd.
  • Bio-Synthesis Inc.
  • PeptiDream Inc.
  • CPC Scientific Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • Circle Pharma
  • Others

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY PEPTIDE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Cyclized Peptides
  • Macrocyclic Peptides
  • D-Peptides
  • Stapled Peptides

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Infectious Diseases
  • Cardiovascular Diseases
  • Cns Disorders
  • Oncology
  • Metabollic Disorders

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY SYNTHESIS METHOD- MARKET ANALYSIS, 2019 - 2032

  • Solid Phase Peptide Synthesis
  • Recombinant Technology

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous
  • Transdermal
  • Subcutaneous

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Research Institutes
  • Pharmaceutical Companies

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Constrained Peptide Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Constrained Peptide Drugs Market Snippet by Peptide Type
    • 2.1.2. Constrained Peptide Drugs Market Snippet by Therapeutic Area
    • 2.1.3. Constrained Peptide Drugs Market Snippet by Synthesis Method
    • 2.1.4. Constrained Peptide Drugs Market Snippet by Route of Administration
    • 2.1.5. Constrained Peptide Drugs Market Snippet by End User
    • 2.1.6. Constrained Peptide Drugs Market Snippet by Country
    • 2.1.7. Constrained Peptide Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Constrained Peptide Drugs Key Market Trends

  • 3.1. Constrained Peptide Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Constrained Peptide Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Constrained Peptide Drugs Market Opportunities
  • 3.4. Constrained Peptide Drugs Market Future Trends

4. Constrained Peptide Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Constrained Peptide Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Constrained Peptide Drugs Market Landscape

  • 6.1. Constrained Peptide Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Constrained Peptide Drugs Market - By Peptide Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Peptide Type, 2024 & 2032 (%)
    • 7.1.2. Cyclized Peptides
    • 7.1.3. Macrocyclic Peptides
    • 7.1.4. D-Peptides
    • 7.1.5. Stapled Peptides

8. Constrained Peptide Drugs Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 8.1.2. Infectious Diseases
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Cns Disorders
    • 8.1.5. Oncology
    • 8.1.6. Metabollic Disorders

9. Constrained Peptide Drugs Market - By Synthesis Method

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Synthesis Method, 2024 & 2032 (%)
    • 9.1.2. Solid Phase Peptide Synthesis
    • 9.1.3. Recombinant Technology

10. Constrained Peptide Drugs Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 10.1.2. Oral
    • 10.1.3. Intravenous
    • 10.1.4. Transdermal
    • 10.1.5. Subcutaneous

11. Constrained Peptide Drugs Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Research Institutes
    • 11.1.4. Pharmaceutical Companies

12. Constrained Peptide Drugs Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Constrained Peptide Drugs Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Constrained Peptide Drugs Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Constrained Peptide Drugs Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Constrained Peptide Drugs Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Constrained Peptide Drugs Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Constrained Peptide Drugs Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Amgen Inc.
    • 13.2.2. Pfizer Inc.
    • 13.2.3. Novartis AG
    • 13.2.4. Merck & Co., Inc.
    • 13.2.5. F. Hoffmann-La Roche Ltd.
    • 13.2.6. Sanofi S.A.
    • 13.2.7. Bicycle Therapeutics PLC
    • 13.2.8. Bristol-Myers Squibb Company
    • 13.2.9. Aileron Therapeutics, Inc.
    • 13.2.10. Eli Lilly and Company
    • 13.2.11. Aileron Therapeutics Inc.
    • 13.2.12. Spexis AG
    • 13.2.13. Santhera Pharmaceuticals
    • 13.2.14. Protagonist Therapeutics Inc.
    • 13.2.15. Union Chimique Belge S.A. (UCB)
    • 13.2.16. Biosynth (Pepscan)
    • 13.2.17. Creative Peptides
    • 13.2.18. Pepticom Ltd.
    • 13.2.19. Bio-Synthesis Inc.
    • 13.2.20. PeptiDream Inc.
    • 13.2.21. CPC Scientific Inc.
    • 13.2.22. Chugai Pharmaceutical Co. Ltd.
    • 13.2.23. Circle Pharma
    • 13.2.24. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us